Assistant Professor, Pathology, Gray Faculty of Medical and Health Sciences, Tel Aviv Sourasky Medical Center, Tel Aviv University Assistant Professor, Neurobiology, Biochemistry and Biophysics, George S. Wise Faculty of Life […]
Assistant Professor, Department of Medicine (Pulmonary, Allergy and Critical Care), Perelman School of Medicine, University of Pennsylvania Dr. Jacob Brenner is an Assistant Professor of Medicine in the Division of […]
Emeritus Professor, Department of Medicine (Hematology-Oncology), Perelman School of Medicine, University of Pennsylvania Dr. James Hoxie is Emeritus Professor of Medicine in the Division of Hematology-Oncology and Co-Director of the […]
Sir Deryck and Lady Va Maughan Professor of Rheumatology, Department of Medicine, NYU Grossman School of Medicine / NYU Langone Health Director, Division of Rheumatology, NYU Grossman School of Medicine […]
Paul B. Beeson Professor of Medicine (Rheumatology), Department of Internal Medicine (Rheumatology, Allergy & Immunology), Yale School of Medicine, Yale University Professor of Immunobiology, Department of Immunobiology, Yale School of […]
Building a fluorescence-based cellular screening platform to identify small molecules targeting mutant UBA1, this project addresses an acute unmet need in VEXAS syndrome and lays groundwork for broader rheumatic disease therapies.
Using single-molecule imaging to visualize B cell receptor signaling across gut compartments, this project uncovers how intestinal B cell education breaks down in IBD, revealing new targets for therapeutic intervention.
Identifying a novel molecular regulator of tolerogenic dendritic cell function, this project uncovers how its loss triggers spontaneous multiorgan autoimmunity and exacerbates lupus — revealing a clinically relevant pathway in immune tolerance.
A self-replicating RNA platform delivers anti-inflammatory cytokines directly to the airways, offering targeted local immune suppression without systemic toxicity — a mechanistically distinct approach to treating lupus lung disease.
Targeting the calcineurin-NFAT protein-protein interaction rather than enzyme active sites, this project develops a novel class of inhibitors to treat steroid-refractory ulcerative colitis with fewer side effects.
